ProfileGDS5678 / 1417211_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 75% 76% 78% 79% 77% 74% 80% 74% 77% 74% 76% 77% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2837378
GSM967853U87-EV human glioblastoma xenograft - Control 25.0043175
GSM967854U87-EV human glioblastoma xenograft - Control 35.0858576
GSM967855U87-EV human glioblastoma xenograft - Control 45.5000678
GSM967856U87-EV human glioblastoma xenograft - Control 55.5853479
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0704477
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.802774
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6145980
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9027874
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3087777
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7789374
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1594976
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1863577
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.86474